Related Experiment Video
Updated: Feb 16, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Production of human single-chain fragment antibody (ScFv) against human epidermal growth factor receptor-2 (HER-2) by
Saeideh Foroumadi1, Masoumeh Rajabibazl2,3, Azam Rahimpour4
1Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Breast cancer with more than 1.7 million diagnoses per year has been known as one of the most prevalent cancers among women worldwide. Despite the availability of advanced treatment options, cancer progression and metastasis is observed in 20% of patients. Human epidermal growth factor receptor-2 (HER-2) is considered as an important prognostic and diagnostic tumor marker for breast cancer. While HER-2 is expressed on the surface of normal cells, its overexpression occurs in 20-25% on breast cancer tumor cells. This type of tumor which is referred to as HER-2+ is the most aggressive type of breast cancer and shows more resistance to radiotherapy. Single-chain fragment antibodies (ScFvs) offer several advantages in comparison to conventional whole antibodies due to their small size. Particularly, ScFv fragments show improved diffusion and solid tumor penetration. In this study, a human ScFv antibody library was used to isolate anti-HER-2 ScFv antibodies through cell panning and mix antigen-cell panning strategies. Analysis of the binding activity and specificity of isolated ScFv antibodies against HER-2-expressing cell lines and recombinant HER-2 antigen indicated the higher efficiency of the cell panning strategy in isolation of ScFv antibody fragments.
Insights
Researchers isolated anti-HER-2 single-chain fragment antibodies (ScFvs) using cell panning. This method proved more effective for identifying ScFvs targeting HER-2+ breast cancer cells.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Breast cancer is a leading global cancer in women, with 20% experiencing progression or metastasis despite treatments.
- Human epidermal growth factor receptor-2 (HER-2) overexpression defines aggressive HER-2+ breast cancer, often resistant to therapy.
- Single-chain fragment antibodies (ScFvs) offer improved tumor penetration compared to conventional antibodies.
Purpose of the Study:
- To isolate human single-chain fragment antibodies (ScFvs) targeting the HER-2 receptor.
- To compare the efficacy of cell panning versus mix antigen-cell panning for ScFV isolation.
Main Methods:
- Utilized a human ScFv antibody library for isolation.
- Employed cell panning and mix antigen-cell panning strategies.
- Analyzed binding activity and specificity of isolated ScFvs against HER-2-expressing cells and recombinant HER-2.
Main Results:
- Successfully isolated anti-HER-2 ScFv antibody fragments.
- Demonstrated the superior efficiency of the cell panning strategy for ScFV isolation.
- Confirmed binding activity and specificity of isolated ScFvs.
Conclusions:
- Cell panning is a highly efficient strategy for isolating specific ScFvs against cell surface targets like HER-2.
- The isolated anti-HER-2 ScFvs hold potential for targeted breast cancer therapy.
- ScFvs represent a promising therapeutic modality for HER-2+ breast cancer due to enhanced tumor penetration.
Related Concept Videos
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
2° Amines to N-Nitrosamines: Reaction with NaNO2
Radical Chain-Growth Polymerization: Chain Branching
Mass Spectrometry: Long-Chain Alkane Fragmentation
Habitat Fragmentation

